VigorFT
VigorFT, licence 80144223: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Melaleuca of Canada Inc.
- NPN or DIN-HM
- 80144223
- Status
- Active licence
- Licence date
- 18 September 2025
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Conditions légales
Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitis vinifera Source : Vitis vinifera - Graine Potency : 95.0 % Proanthocyanidins | 90.5 mg | Not calculated |
| Trigonella foenum-graecum Source : Trigonella foenum-graecum - Graine Extract : Matériel brut sec Extraction ratio : 50:1 Dry plant equivalent : 13.625 g Potency : 20.0 % Protodioscin | 272.5 mg | Not calculated |
| Epimedium sagittatum Potency : 20.0 % Icariin | 28.0 mg | Not calculated |
Non-medicinal ingredients
Hydroxypropyl méthylcellulose, Carraghénine, Dioxyde de silicium, Maltodextrine, Cellulose microcristalline, Eau purifiée, Chlorure de potassium, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Hommes | minimum: 18.0 Année(s) | 2.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Aids in promoting overall energy and vitality in men. Helps maintain normal testosterone levels. Helps promote sexual health. Helps promote testosterone production. Helps support arousal. Helps support normal levels of free testosterone. Helps support testosterone production. Helps to support cardiovascular health. Helps to support healthy reproductive function. Helps to support sperm health. Helps increase testosterone levels within physiological limits. Source of (an) antioxidant(s)/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Source of (an) antioxidant(s)/Provides (an) antioxidant(s). Helps support free testosterone production.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80144223
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.